X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA STRIDES PHARMA SCIENCE ASTRAZENECA PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 64.0 16.1 397.1% View Chart
P/BV x 18.0 1.0 1,892.8% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ASTRAZENECA PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
ASTRAZENECA PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1,2781,147 111.4%   
Low Rs883642 137.5%   
Sales per share (Unadj.) Rs228.4317.2 72.0%  
Earnings per share (Unadj.) Rs10.47.8 132.1%  
Cash flow per share (Unadj.) Rs16.325.1 64.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs98.8274.3 36.0%  
Shares outstanding (eoy) m25.0089.50 27.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.72.8 167.8%   
Avg P/E ratio x104.2114.0 91.4%  
P/CF ratio (eoy) x66.435.7 186.1%  
Price / Book Value ratio x10.93.3 335.3%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m27,00880,058 33.7%   
No. of employees `0001.42.5 54.1%   
Total wages/salary Rs m1,5354,341 35.4%   
Avg. sales/employee Rs Th4,210.911,325.8 37.2%   
Avg. wages/employee Rs Th1,132.21,731.4 65.4%   
Avg. net profit/employee Rs Th191.1280.1 68.2%   
INCOME DATA
Net Sales Rs m5,71028,394 20.1%  
Other income Rs m123941 13.0%   
Total revenues Rs m5,83329,334 19.9%   
Gross profit Rs m4633,965 11.7%  
Depreciation Rs m1471,540 9.6%   
Interest Rs m01,962 0.0%   
Profit before tax Rs m4381,403 31.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m17997 183.9%   
Profit after tax Rs m259702 36.9%  
Gross profit margin %8.114.0 58.0%  
Effective tax rate %40.86.9 589.0%   
Net profit margin %4.52.5 183.5%  
BALANCE SHEET DATA
Current assets Rs m3,20924,836 12.9%   
Current liabilities Rs m2,07018,993 10.9%   
Net working cap to sales %20.020.6 97.0%  
Current ratio x1.61.3 118.6%  
Inventory Days Days7271 101.9%  
Debtors Days Days35113 30.8%  
Net fixed assets Rs m79034,289 2.3%   
Share capital Rs m50895 5.6%   
"Free" reserves Rs m2,41923,651 10.2%   
Net worth Rs m2,46924,546 10.1%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m4,60565,437 7.0%  
Interest coverage xNM1.7-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.20.4 285.7%   
Return on assets %5.64.1 138.2%  
Return on equity %10.52.9 366.8%  
Return on capital %17.76.9 257.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30015,697 1.9%   
Fx outflow Rs m2,015735 274.0%   
Net fx Rs m-1,71514,962 -11.5%   
CASH FLOW
From Operations Rs m881,871 4.7%  
From Investments Rs m-945,826 -1.6%  
From Financial Activity Rs mNA-10,157 0.0%  
Net Cashflow Rs m-6-2,615 0.2%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 37.8 0.8%  
FIIs % 15.7 8.6 182.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 25.9 35.1%  
Shareholders   12,856 56,241 22.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Realty and Metal Stocks Lag(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.1% while the Hang Seng is flat.

Related Views on News

EDELWEISS FINANCIAL Plunges by 5%; BSE 500 Index Down 0.1% (Market Updates)

Aug 21, 2019 | Updated on Aug 21, 2019

EDELWEISS FINANCIAL share price has plunged by 5% and its current market price is Rs 120. The BSE 500 is down by 0.1%. The top gainers in the BSE 500 Index are JAGRAN PRAKASHAN (up 5.6%) and MAHINDRA CIE AUTO. (up 4.4%). The top losers are EDELWEISS FINANCIAL (down 5.4%) and ASTRAZENECA PHARMA (down 6.0%).

ASTRAZENECA PHARMA Plunges by 6%; BSE HEALTHCARE Index Down 0.1% (Market Updates)

Aug 21, 2019 | Updated on Aug 21, 2019

ASTRAZENECA PHARMA share price has plunged by 6% and its current market price is Rs 1,757. The BSE HEALTHCARE is down by 0.1%. The top gainers in the BSE HEALTHCARE Index are BIOCON (up 2.7%) and ALEMBIC PHARMA (up 2.2%). The top losers is ASTRAZENECA PHARMA (down 6.0%)..

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

The Perfect Stock in the Rebirth of India(The 5 Minute Wrapup)

Aug 8, 2019

This debt-free, well-managed company is all set to soar.

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 21, 2019 10:15 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS